Thyroid Cancer in a Psoriatic Patient Treated With Secukinumab: A Case Report and Literature Review
Year: 2025
Type: article
Study design: Case Report
Abstract: Biologics are a key treatment option for managing chronic inflammatory and autoimmune diseases, especially moderate to severe psoriasis. While studies have not definitively proven a causal link between biologics and cancer, concerns remain regarding their potential association with an increased risk of certain malignancies. This report describes an observed temporal association in a patient with psoriasis who was treated with the interleukin-17A inhibitor secukinumab for four years and subsequently developed metastatic medullary thyroid cancer.
Source: Cureus
DOI: 10.7759/cureus.93590
Authors: Areej Alyousef, Hussein Attia, Mutlaq Alsulaili, Shehab Aldhafiri, Hamdy Sakr
Institutions: Jahra Hospital, Kuwait Cancer Control Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4414644237